oculoleptomeningeal type amyloidosis (amyloidosis VII)

From Aaushi
Jump to navigation Jump to search

Pathology

Genetics

Clinical manifestations

Management

More general terms

Additional terms

References

  1. OMIM https://mirror.omim.org/entry/105210
  2. 2.0 2.1 Coelho T et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013 Aug 29; 369:819 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23984729 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1208760
    Lachmann HJ. A new era in the treatment of amyloidosis? N Engl J Med 2013 Aug 29; 369:866 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23984734 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1308768
  3. Yasgur BS New Agents Show Promise for Severe and Fatal Genetic Disease. Medscape - Jul 10, 2018. https://www.medscape.com/viewarticle/899112

Database